Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of bimekizumab in active psoriatic arthritis after TNF inhibitor inadequate response or intolerance
jRCT2080224796Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) and psoriasis comparing Bimekizumab with Placebo (2 arms). Started Jul 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)psoriasis
Beyond the preview
Go deeper on jRCT2080224796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224796.